About Paragon BioTeck
Paragon BioTeck is a Healthcare company based in Portland (United States) founded in 2009, and was acquired by Bausch & Lomb in November 2022. US-based, private pharma company that develops products for Dry Eye Disease and Ocular Surface Disease. The company has 15 employees. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is PARAGON BIOTECK, INC. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Paragon BioTeck was founded in 2009 as a private pharmaceutical company based in Portland, United States. Focus is placed on the development of diagnostic, management, and treatment solutions for dry eye disease and ocular surface disease. Branded over-the-counter and prescription products are manufactured, including punctal occlusion plugs. Operations center on ocular condition therapies within the pharmaceutical sector.
- Headquarters Portland, United States
- Employees 15
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website paragonbioteck.com
- Social LinkedIn X Facebook
- Acquired by Bausch & Lomb (Nov 2022)
- Legal Name Paragon Bioteck, Inc.
- Investors
- Employee Count15
- Acquired byBausch & Lomb
(Nov 2022)
Investors in Paragon BioTeck
Paragon BioTeck has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bausch & Lomb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States |
Investor details for Paragon BioTeck
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Paragon BioTeck
2 people are tracked at Paragon BioTeck (2 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Patrick Witham | Chairman and Chief Executive Officer | Leadership |
Travis Sydow | Executive Vice President & General Counsel | Leadership |
Complete people profiles for Paragon BioTeck
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Paragon BioTeck
2 dated milestones of Paragon BioTeck across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Paragon BioTeck is founded.
- Exit Acquired by Bausch & Lomb.
Competitors of Paragon BioTeck
Paragon BioTeck has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Paragon BioTeck
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Paragon BioTeck (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Paragon Bioteck
Complete news archive for Paragon BioTeck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Paragon BioTeck
Paragon BioTeck was founded in 2009.
Paragon BioTeck is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
Paragon BioTeck has 15 employees.
Paragon BioTeck was founded in 2009 as a private pharmaceutical company based in Portland, United States. Focus is placed on the development of diagnostic, management, and treatment solutions for dry eye disease and ocular surface disease. Branded over-the-counter and prescription products are manufactured, including punctal occlusion plugs. Operations center on ocular condition therapies within the pharmaceutical sector.
Paragon BioTeck's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
Paragon BioTeck has 1 investor. Key investors include Bausch & Lomb.
Paragon BioTeck operates through Paragon Bioteck, Inc..
Yes. Paragon BioTeck was acquired by Bausch & Lomb in November 2022.